Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > SEC Filing

<< Previous

Bullboard Posts

Next >>

Comment by jh1970on Sep 06, 2024 3:42pm

131 Views

Post# 36212370

RE:RE:SEC Filing

This is not what you post it.This is it from SEC filing on the ONC web page .
Report of Foreign Private Issuer
6-K 1 form6ksep2024confpr.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number 001-38512 Oncolytics Biotech Inc. (Translation of registrant's name into English) Suite 804, 322 11th Avenue SW Calgary, Alberta, Canada T2R 0C5 (Address of principal executive offices)

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec